Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

IASO and Innovent Approved to Start Trial of Novel CAR-T Immunotherapy

publication date: Oct 2, 2019

IASO Biotherapeutics of Nanjing and its partner, Suzhou Innovent Biologics, announced that their jointly developed CAR-T therapy was approved to start a Phase Ib/II trial in China in patients with relapsed/refractory multiple myeloma. IASO said CT103A was designed for rr/mm patients who have relapsed after CAR-T treatment. Because repeat CAR-T rounds are not effective, CT103A was developed using a lentiviral vector containing a CAR structure. IASO said 7 out of 8 evaluable patients in a China IIT study achieved very good partial response or better. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.